CD244 and prostate adenocarcinoma: In contrast, other tumors such as PCPG, LIHC, KIRP, glioblastoma multiforme (GBM), COAD, BLCA, SARC, prostate adenocarcinoma (PRAD), BRCA, thyroid carcinoma (THCA), UCEC, HNSC, and TGCT showed relatively lower methylation levels of CD244.